Ontology highlight
ABSTRACT: Background
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC).Methods
82 consecutive patients treated with icotinib as first (n?=?24) or second/third line (n?=?58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method.Results
Median PFS was 4.0 months (95% CI 2.311-5.689). Median OS was 11.0 months (95% CI 8.537-13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151-11.8) and 3.0 months (95% CI 1.042-4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305-15.695) and 10.0 months (95% CI 7.295-12.70), respectively. In patients with EGFR mutation (n?=?19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18-0.70, p?=?0.003) and death (HR 0.10, 95% CI 0.02-0.42, p?=?0.002) compared with those EGFR status unknown (n?=?63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%).Conclusions
Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.
SUBMITTER: Chen X
PROVIDER: S-EPMC4023939 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
Chen Xiaofeng X Zhu Quan Q Liu Yiqian Y Liu Ping P Yin Yongmei Y Guo Renhua R Lu Kaihua K Gu Yanhong Y Liu Lianke L Wang Jinghua J Wang Zhaoxia Z Røe Oluf Dimitri OD Shu Yongqian Y Zhu Lingjun L
PloS one 20140516 5
<h4>Background</h4>Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC).<h4>Methods</h4>82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into ...[more]